Karolinska Interventional Study of Mammograhic Density (Karisma-1)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures. It is known that a density change is seen after 12 months of 20 mg of tamoxifen, but the clinical experience indicates that an effect of drugs influencing mammographic density could be seen already after a few months. The second aim is to evaluate if there is a density change from 10 mg of tamoxifen equivalent to 20 mg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low Dose Tamoxifen for Mammographic Density Reduction

NCT03346200

Risk Reduction Mammographic Density Reduction

COMPLETED PHASE2

Therapeutic Dose Monitoring (TDM) of Tamoxifen

NCT05133674

Breast Cancer Breast Carcinoma Breast Tumors +2 more

UNKNOWN PHASE2

Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen

NCT07145827

Breast Cancer Endometrial Hyperplasia and Endometrial Cancers

COMPLETED NA

Long-term Follow-up of the TAM-01 Study

NCT06982313

Breast Cancer Invasive

NOT_YET_RECRUITING

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer

NCT00086749

Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators want to conduct a feasibility study including 42 women who will be randomised to either 10 or 20 mg of daily oral tamoxifen. The primary aim of the study is to identify the time to mammographic density change and piloting the procedures. It is known that a density change is seen after 12 months of 20 mg of daily tamoxifen, but the clinical experience indicates that an effect of drugs influencing mammographic density could be seen already after a few months. The second aim of the pilot study is to see if there is a density change from 10 mg of tamoxifen equivalent to 20 mg and if there is a difference in adverse reactions between the two doses. Interim analysis will be performed at 6 months, monitoring both safety and level of mammographic density change.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Mammographic Density

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Clinical Trial

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tamoxifen 10mg

Randomised dose of daily oral Tamoxifen 10mg, for 180 days

Group Type EXPERIMENTAL

Tamoxifen

Intervention Type DRUG

A registered SERM drug, Tamoxifen.

Tamoxifen 20mg

Randomised dose of daily oral Tamoxifen 20mg, for 180 days

Group Type ACTIVE_COMPARATOR

Tamoxifen

Intervention Type DRUG

A registered SERM drug, Tamoxifen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tamoxifen

A registered SERM drug, Tamoxifen.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously participated in the Karma study
* Attending the national mammography screening program, i.e. aged 40-74
* A mammogram, including a stored raw image, must have been taken within 3 weeks of baseline and start of therapy
* Having a mammographic volumetric density above the lowest 1/6, measured by Volpara
* Informed consent must be signed before any study specific assessments have been performed

Exclusion Criteria

* Being pregnant or planning to become pregnant during the study
* Any previous or current diagnosis of breast cancer (including carcinoma in situ)
* Recalled (mammographic code 3 or above) after baseline screening mammography
* Any previous diagnosis of cancer, with the exception of non-melanoma skin cancer and in situ cancer of the cervix
* Currently using oestrogen and progesterone-based hormone replacement therapy
* Current use of hormone contraceptive with hormones, e.g. hormonal contraceptive pills, or progesterone implants. Hormonal intrauterine devices are accepted.
* A history of thromboembolic disease such as embolism, deep vein thrombosis, stroke, TIA or cardiac arrest.
* A history of immobilization, e.g. using wheelchair
* Uncontrolled diabetes defined as known untreated diabetes
* Hypertension at baseline, defined as systolic pressure higher than 140 mm Hg and diastolic higher than 90 mm Hg
* Use of drugs that interfere with CYP2D6 expression such as paroxetine, fluoxetine and bupropion

Minimum Eligible Age

40 Years

Maximum Eligible Age

74 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes